ID   PGM1_HUMAN              Reviewed;         562 AA.
AC   P36871; B2R5N9; B4DPV0; Q16105; Q16106; Q5BKZ9; Q6NW22; Q86U74;
AC   Q96J40; Q9NTY4;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Phosphoglucomutase-1;
DE            Short=PGM 1;
DE            EC=5.4.2.2 {ECO:0000269|PubMed:15378030, ECO:0000269|PubMed:25288802};
DE   AltName: Full=Glucose phosphomutase 1;
GN   Name=PGM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Skeletal muscle;
RX   PubMed=1530890; DOI=10.1073/pnas.89.1.411;
RA   Whitehouse D.B., Putt W., Lovegrove J.U., Morrison K.E., Hollyoake M.,
RA   Fox M.F., Hopkinson D.A., Edwards Y.H.;
RT   "Phosphoglucomutase 1: complete human and rabbit mRNA sequences and
RT   direct mapping of this highly polymorphic marker on human chromosome
RT   1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:411-415(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   CYS-221 AND HIS-420.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3), AND VARIANT
RP   HIS-420.
RC   TISSUE=Astrocyte, and Mesangial cell;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   CYS-221 AND HIS-420.
RC   TISSUE=Cervix, Hypothalamus, Placenta, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-82 (ISOFORMS 1 AND 2), AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=8257433; DOI=10.1042/bj2960417;
RA   Putt W., Ives J.H., Hollyoake M., Hopkinson D.A., Whitehouse D.B.,
RA   Edwards Y.H.;
RT   "Phosphoglucomutase 1: a gene with two promoters and a duplicated
RT   first exon.";
RL   Biochem. J. 296:417-422(1993).
RN   [7]
RP   PHOSPHORYLATION AT THR-467, AND CATALYTIC ACTIVITY.
RX   PubMed=15378030; DOI=10.1038/sj.onc.1207969;
RA   Gururaj A., Barnes C.J., Vadlamudi R.K., Kumar R.;
RT   "Regulation of phosphoglucomutase 1 phosphorylation and activity by a
RT   signaling kinase.";
RL   Oncogene 23:8118-8127(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa
RT   cells and high confident phosphopeptide identification by cross-
RT   validation of MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-117, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-16, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-117, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1 (ISOFORM 2),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-117, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-185; SER-201; SER-206;
RP   SER-378; SER-505 AND SER-509, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF WILD-TYPE; VARIANT CDG1T
RP   ARG-121 AND VARIANT ARG-291 IN COMPLEX WITH MAGNESIUM, AND COFACTOR.
RX   PubMed=26972339; DOI=10.1016/j.jmb.2016.02.032;
RA   Stiers K.M., Kain B.N., Graham A.C., Beamer L.J.;
RT   "Induced structural disorder as a molecular mechanism for enzyme
RT   dysfunction in phosphoglucomutase 1 deficiency.";
RL   J. Mol. Biol. 428:1493-1505(2016).
RN   [20]
RP   VARIANTS MET-68; CYS-221 AND HIS-420.
RX   PubMed=7902567; DOI=10.1073/pnas.90.22.10725;
RA   Takahashi N., Neels J.V.;
RT   "Intragenic recombination at the human phosphoglucomutase 1 locus:
RT   predictions fulfilled.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10725-10729(1993).
RN   [21]
RP   VARIANTS CYS-221 AND HIS-420.
RX   PubMed=7902568; DOI=10.1073/pnas.90.22.10730;
RA   March R.E., Putt W., Hollyoake M., Ives J.H., Lovegrove J.U.,
RA   Hopkinson D.A., Edwards Y.H., Whitehouse D.B.;
RT   "The classical human phosphoglucomutase (PGM1) isozyme polymorphism is
RT   generated by intragenic recombination.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10730-10733(1993).
RN   [22]
RP   INVOLVEMENT IN CDG1T, AND VARIANT CDG1T ALA-115.
RX   PubMed=19625727; DOI=10.1056/NEJMc0901158;
RA   Stojkovic T., Vissing J., Petit F., Piraud M., Orngreen M.C.,
RA   Andersen G., Claeys K.G., Wary C., Hogrel J.Y., Laforet P.;
RT   "Muscle glycogenosis due to phosphoglucomutase 1 deficiency.";
RL   N. Engl. J. Med. 361:425-427(2009).
RN   [23]
RP   VARIANT CDG1T ARG-121.
RX   PubMed=22492991; DOI=10.1093/hmg/dds123;
RA   Timal S., Hoischen A., Lehle L., Adamowicz M., Huijben K.,
RA   Sykut-Cegielska J., Paprocka J., Jamroz E., van Spronsen F.J.,
RA   Korner C., Gilissen C., Rodenburg R.J., Eidhof I., Van den Heuvel L.,
RA   Thiel C., Wevers R.A., Morava E., Veltman J., Lefeber D.J.;
RT   "Gene identification in the congenital disorders of glycosylation type
RT   I by whole-exome sequencing.";
RL   Hum. Mol. Genet. 21:4151-4161(2012).
RN   [24]
RP   VARIANT CDG1T ARG-291.
RX   PubMed=22976764; DOI=10.1007/s10545-012-9525-7;
RA   Perez B., Medrano C., Ecay M.J., Ruiz-Sala P., Martinez-Pardo M.,
RA   Ugarte M., Perez-Cerda C.;
RT   "A novel congenital disorder of glycosylation type without central
RT   nervous system involvement caused by mutations in the
RT   phosphoglucomutase 1 gene.";
RL   J. Inherit. Metab. Dis. 36:535-542(2013).
RN   [25]
RP   VARIANTS CDG1T ALA-19; TYR-38; ARG-41; HIS-62; ALA-115; ARG-121;
RP   TYR-263; GLY-263; ARG-291; ARG-330; LYS-377; LYS-388 AND PRO-516.
RX   PubMed=24499211; DOI=10.1056/NEJMoa1206605;
RA   Tegtmeyer L.C., Rust S., van Scherpenzeel M., Ng B.G., Losfeld M.E.,
RA   Timal S., Raymond K., He P., Ichikawa M., Veltman J., Huijben K.,
RA   Shin Y.S., Sharma V., Adamowicz M., Lammens M., Reunert J., Witten A.,
RA   Schrapers E., Matthijs G., Jaeken J., Rymen D., Stojkovic T.,
RA   Laforet P., Petit F., Aumaitre O., Czarnowska E., Piraud M.,
RA   Podskarbi T., Stanley C.A., Matalon R., Burda P., Seyyedi S.,
RA   Debus V., Socha P., Sykut-Cegielska J., van Spronsen F.,
RA   de Meirleir L., Vajro P., DeClue T., Ficicioglu C., Wada Y.,
RA   Wevers R.A., Vanderschaeghe D., Callewaert N., Fingerhut R.,
RA   van Schaftingen E., Freeze H.H., Morava E., Lefeber D.J.,
RA   Marquardt T.;
RT   "Multiple phenotypes in phosphoglucomutase 1 deficiency.";
RL   N. Engl. J. Med. 370:533-542(2014).
RN   [26]
RP   CHARACTERIZATION OF VARIANTS CDG1T ALA-19; TYR-38; ARG-41; HIS-62;
RP   ALA-115; ARG-121; GLY-263; TYR-263; ARG-291; ARG-330; LYS-377; LYS-388
RP   AND PRO-516, VARIANTS MET-68; CYS-221 AND HIS-420, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, ACTIVE SITE, PHOSPHORYLATION AT
RP   SER-117, AND ENZYME REGULATION.
RX   PubMed=25288802; DOI=10.1074/jbc.M114.597914;
RA   Lee Y., Stiers K.M., Kain B.N., Beamer L.J.;
RT   "Compromised catalysis and potential folding defects in in vitro
RT   studies of missense mutants associated with hereditary
RT   phosphoglucomutase 1 deficiency.";
RL   J. Biol. Chem. 289:32010-32019(2014).
CC   -!- FUNCTION: This enzyme participates in both the breakdown and
CC       synthesis of glucose.
CC   -!- CATALYTIC ACTIVITY: Alpha-D-glucose 1-phosphate = alpha-D-glucose
CC       6-phosphate. {ECO:0000269|PubMed:15378030,
CC       ECO:0000269|PubMed:25288802}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:26972339};
CC       Note=Binds 1 Mg(2+) ion per subunit.
CC       {ECO:0000269|PubMed:26972339};
CC   -!- ENZYME REGULATION: Glucose-1,6-bisphosphate enhances
CC       phosphorylation of the active site Ser-117, and thereby increases
CC       enzyme activity. {ECO:0000269|PubMed:25288802}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=80 uM for alpha-D-glucose 1-phosphate
CC         {ECO:0000269|PubMed:25288802};
CC   -!- SUBUNIT: Monomer.
CC   -!- INTERACTION:
CC       Q9BSI4:TINF2; NbExp=2; IntAct=EBI-2861475, EBI-717399;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P36871-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P36871-2; Sequence=VSP_004686;
CC         Note=Contains a N-acetylmethionine at position 1.
CC         {ECO:0000244|PubMed:21406692};
CC       Name=3;
CC         IsoId=P36871-3; Sequence=VSP_045204;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Phosphorylation at Thr-467 by PAK1 significantly enhances
CC       enzymatic activity. {ECO:0000269|PubMed:15378030}.
CC   -!- POLYMORPHISM: Many polymorphic variants of PGM1 exist. 8 different
CC       alleles are known: PGM1*1+, PGM1*1-, PGM1*2+, PGM1*2-, PGM1*3+,
CC       PGM1*3-, PGM1*7+ and PGM1*7-. The sequence of PGM1*1+ is shown
CC       here.
CC   -!- DISEASE: Congenital disorder of glycosylation 1T (CDG1T)
CC       [MIM:614921]: A form of congenital disorder of glycosylation, a
CC       multisystem disorder caused by a defect in glycoprotein
CC       biosynthesis and characterized by under-glycosylated serum
CC       glycoproteins. Congenital disorders of glycosylation result in a
CC       wide variety of clinical features, such as defects in the nervous
CC       system development, psychomotor retardation, dysmorphic features,
CC       hypotonia, coagulation disorders, and immunodeficiency. The broad
CC       spectrum of features reflects the critical role of N-glycoproteins
CC       during embryonic development, differentiation, and maintenance of
CC       cell functions. {ECO:0000269|PubMed:19625727,
CC       ECO:0000269|PubMed:22492991, ECO:0000269|PubMed:22976764,
CC       ECO:0000269|PubMed:24499211, ECO:0000269|PubMed:25288802,
CC       ECO:0000269|PubMed:26972339}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the phosphohexose mutase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH90856.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M83088; AAA60080.1; -; mRNA.
DR   EMBL; BT006961; AAP35607.1; -; mRNA.
DR   EMBL; AK298505; BAG60712.1; -; mRNA.
DR   EMBL; AK312254; BAG35186.1; -; mRNA.
DR   EMBL; AL109925; CAB92085.1; -; Genomic_DNA.
DR   EMBL; AL109925; CAB92086.1; -; Genomic_DNA.
DR   EMBL; BC001756; AAH01756.3; -; mRNA.
DR   EMBL; BC019920; AAH19920.1; -; mRNA.
DR   EMBL; BC067763; AAH67763.2; -; mRNA.
DR   EMBL; BC090856; AAH90856.1; ALT_INIT; mRNA.
DR   EMBL; S67989; AAB29177.2; -; Genomic_DNA.
DR   EMBL; S67998; AAB29178.1; -; Genomic_DNA.
DR   CCDS; CCDS53323.1; -. [P36871-2]
DR   CCDS; CCDS53324.1; -. [P36871-3]
DR   CCDS; CCDS625.1; -. [P36871-1]
DR   PIR; A41801; A41801.
DR   PIR; S39397; S39397.
DR   RefSeq; NP_001166289.1; NM_001172818.1. [P36871-2]
DR   RefSeq; NP_001166290.1; NM_001172819.1. [P36871-3]
DR   RefSeq; NP_002624.2; NM_002633.2. [P36871-1]
DR   UniGene; Hs.1869; -.
DR   PDB; 5EPC; X-ray; 1.85 A; A/B=1-562.
DR   PDB; 5F9C; X-ray; 2.50 A; A/B=1-562.
DR   PDB; 5HSH; X-ray; 2.65 A; A/B=1-562.
DR   PDB; 5JN5; X-ray; 1.75 A; A/B=1-562.
DR   PDB; 5TR2; X-ray; 2.50 A; A/B=1-562.
DR   PDBsum; 5EPC; -.
DR   PDBsum; 5F9C; -.
DR   PDBsum; 5HSH; -.
DR   PDBsum; 5JN5; -.
DR   PDBsum; 5TR2; -.
DR   ProteinModelPortal; P36871; -.
DR   SMR; P36871; -.
DR   BioGrid; 111256; 44.
DR   DIP; DIP-60903N; -.
DR   IntAct; P36871; 9.
DR   MINT; MINT-5001559; -.
DR   DrugBank; DB04397; Alpha-D-Glucose-1-Phosphate-6-Vanadate.
DR   iPTMnet; P36871; -.
DR   PhosphoSitePlus; P36871; -.
DR   SwissPalm; P36871; -.
DR   BioMuta; PGM1; -.
DR   DMDM; 585670; -.
DR   REPRODUCTION-2DPAGE; P36871; -.
DR   EPD; P36871; -.
DR   MaxQB; P36871; -.
DR   PeptideAtlas; P36871; -.
DR   PRIDE; P36871; -.
DR   TopDownProteomics; P36871-1; -. [P36871-1]
DR   DNASU; 5236; -.
DR   Ensembl; ENST00000371083; ENSP00000360124; ENSG00000079739. [P36871-2]
DR   Ensembl; ENST00000371084; ENSP00000360125; ENSG00000079739. [P36871-1]
DR   Ensembl; ENST00000540265; ENSP00000443449; ENSG00000079739. [P36871-3]
DR   GeneID; 5236; -.
DR   KEGG; hsa:5236; -.
DR   UCSC; uc001dbh.5; human. [P36871-1]
DR   CTD; 5236; -.
DR   DisGeNET; 5236; -.
DR   GeneCards; PGM1; -.
DR   GeneReviews; PGM1; -.
DR   HGNC; HGNC:8905; PGM1.
DR   HPA; CAB004666; -.
DR   HPA; HPA024190; -.
DR   HPA; HPA024637; -.
DR   HPA; HPA046329; -.
DR   MalaCards; PGM1; -.
DR   MIM; 171900; gene.
DR   MIM; 614921; phenotype.
DR   neXtProt; NX_P36871; -.
DR   OpenTargets; ENSG00000079739; -.
DR   Orphanet; 711; Glycogen storage disease due to phosphoglucomutase deficiency.
DR   Orphanet; 319646; PGM-CDG.
DR   PharmGKB; PA33242; -.
DR   GeneTree; ENSGT00390000011831; -.
DR   HOVERGEN; HBG001599; -.
DR   InParanoid; P36871; -.
DR   KO; K01835; -.
DR   OMA; PAYSKGI; -.
DR   OrthoDB; EOG091G0HZ0; -.
DR   PhylomeDB; P36871; -.
DR   TreeFam; TF300350; -.
DR   BioCyc; MetaCyc:HS01335-MONOMER; -.
DR   Reactome; R-HSA-3322077; Glycogen synthesis.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-70221; Glycogen breakdown (glycogenolysis).
DR   Reactome; R-HSA-70370; Galactose catabolism.
DR   SABIO-RK; P36871; -.
DR   SIGNOR; P36871; -.
DR   ChiTaRS; PGM1; human.
DR   GeneWiki; PGM1; -.
DR   GenomeRNAi; 5236; -.
DR   PRO; PR:P36871; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000079739; -.
DR   CleanEx; HS_PGM1; -.
DR   Genevisible; P36871; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; NAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004614; F:phosphoglucomutase activity; IDA:UniProtKB.
DR   GO; GO:0019388; P:galactose catabolic process; IBA:GO_Central.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IDA:UniProtKB.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IBA:GO_Central.
DR   GO; GO:0005980; P:glycogen catabolic process; TAS:Reactome.
DR   GO; GO:0006096; P:glycolytic process; TAS:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   Gene3D; 3.30.310.50; -; 1.
DR   InterPro; IPR005844; A-D-PHexomutase_a/b/a-I.
DR   InterPro; IPR016055; A-D-PHexomutase_a/b/a-I/II/III.
DR   InterPro; IPR005845; A-D-PHexomutase_a/b/a-II.
DR   InterPro; IPR005846; A-D-PHexomutase_a/b/a-III.
DR   InterPro; IPR005843; A-D-PHexomutase_C.
DR   InterPro; IPR016066; A-D-PHexomutase_CS.
DR   InterPro; IPR005841; Alpha-D-phosphohexomutase_SF.
DR   Pfam; PF02878; PGM_PMM_I; 1.
DR   Pfam; PF02879; PGM_PMM_II; 1.
DR   Pfam; PF02880; PGM_PMM_III; 1.
DR   Pfam; PF00408; PGM_PMM_IV; 1.
DR   PRINTS; PR00509; PGMPMM.
DR   SUPFAM; SSF53738; SSF53738; 3.
DR   SUPFAM; SSF55957; SSF55957; 1.
DR   PROSITE; PS00710; PGM_PMM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Carbohydrate metabolism; Complete proteome;
KW   Congenital disorder of glycosylation; Cytoplasm; Disease mutation;
KW   Glucose metabolism; Glycogen storage disease; Isomerase; Magnesium;
KW   Metal-binding; Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    562       Phosphoglucomutase-1.
FT                                /FTId=PRO_0000147776.
FT   REGION      117    118       Substrate binding.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   REGION      292    293       Substrate binding.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   REGION      376    378       Substrate binding.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   ACT_SITE    117    117       Phosphoserine intermediate.
FT                                {ECO:0000269|PubMed:25288802}.
FT   METAL       117    117       Magnesium; via phosphate group.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   METAL       288    288       Magnesium. {ECO:0000269|PubMed:26972339}.
FT   METAL       290    290       Magnesium. {ECO:0000269|PubMed:26972339}.
FT   METAL       292    292       Magnesium. {ECO:0000269|PubMed:26972339}.
FT   BINDING      19     19       Substrate.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   BINDING      23     23       Substrate.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   BINDING     130    130       Substrate.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   BINDING     357    357       Substrate.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   BINDING     389    389       Substrate.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   BINDING     515    515       Substrate.
FT                                {ECO:0000250|UniProtKB:P00949}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES      16     16       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     115    115       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9D0F9}.
FT   MOD_RES     117    117       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000269|PubMed:25288802}.
FT   MOD_RES     134    134       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P38652}.
FT   MOD_RES     185    185       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     201    201       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     206    206       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     213    213       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P38652}.
FT   MOD_RES     349    349       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9D0F9}.
FT   MOD_RES     353    353       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q9D0F9}.
FT   MOD_RES     369    369       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P38652}.
FT   MOD_RES     378    378       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     419    419       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q9D0F9}.
FT   MOD_RES     467    467       Phosphothreonine; by PAK1.
FT                                {ECO:0000269|PubMed:15378030}.
FT   MOD_RES     477    477       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P38652}.
FT   MOD_RES     485    485       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P38652}.
FT   MOD_RES     505    505       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     507    507       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9D0F9}.
FT   MOD_RES     509    509       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     541    541       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P38652}.
FT   VAR_SEQ       1    197       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_045204.
FT   VAR_SEQ       1     77       MVKIVTVKTQAYQDQKPGTSGLRKRVKVFQSSANYAENFIQ
FT                                SIISTVEPAQRQEATLVVGGDGRFYMKEAIQLIARI -> M
FT                                SDFEEWISGTYRKMEEGPLPLLTFATAPYHDQKPGTSGLRK
FT                                KTYYFEEKPCYLENFIQSIFFSIDLKDRQGSSLVVGGDGRY
FT                                FNKSAIETIVQM (in isoform 2).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_004686.
FT   VARIANT      19     19       T -> A (in CDG1T; reduces strongly
FT                                phosphoglucomutase activity).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071635.
FT   VARIANT      38     38       N -> Y (in CDG1T; reduces strongly
FT                                solubility; increases aggregation;
FT                                dbSNP:rs587777402).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071636.
FT   VARIANT      41     41       Q -> R (in CDG1T; reduces solubility;
FT                                increases aggregation).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071637.
FT   VARIANT      62     62       D -> H (in CDG1T; reduces solubility;
FT                                reduces strongly phosphoglucomutase
FT                                activity; dbSNP:rs587777403).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071638.
FT   VARIANT      68     68       K -> M (in allele PGM1*7+, allele
FT                                PGM1*7-, allele PGM1*3+ and allele
FT                                PGM1*3-; phosphoglucomutase activity is
FT                                similar to wild-type; dbSNP:rs200390982).
FT                                {ECO:0000269|PubMed:25288802,
FT                                ECO:0000269|PubMed:7902567}.
FT                                /FTId=VAR_006090.
FT   VARIANT      88     88       I -> V (in dbSNP:rs855314).
FT                                /FTId=VAR_050496.
FT   VARIANT     115    115       T -> A (in CDG1T; reduces mildly
FT                                phosphoglucomutase activity;
FT                                dbSNP:rs121918371).
FT                                {ECO:0000269|PubMed:19625727,
FT                                ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_062280.
FT   VARIANT     121    121       G -> R (in CDG1T; there is 7% enzyme
FT                                residual phosphoglucomutase activity;
FT                                dbSNP:rs398122912).
FT                                {ECO:0000269|PubMed:22492991,
FT                                ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_069219.
FT   VARIANT     221    221       R -> C (in allele PGM1*2+, allele
FT                                PGM1*2-, allele PGM1*3+ and allele
FT                                PGM1*3-; phosphoglucomutase activity is
FT                                similar to wild-type; dbSNP:rs1126728).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:25288802,
FT                                ECO:0000269|PubMed:7902567,
FT                                ECO:0000269|PubMed:7902568,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_006091.
FT   VARIANT     263    263       D -> G (in CDG1T; reduces strongly
FT                                phosphoglucomutase activity).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071639.
FT   VARIANT     263    263       D -> Y (in CDG1T; reduces strongly
FT                                phosphoglucomutase activity;
FT                                dbSNP:rs587777404).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071640.
FT   VARIANT     291    291       G -> R (in CDG1T; reduces strongly
FT                                phosphoglucomutase activity;
FT                                dbSNP:rs772768778).
FT                                {ECO:0000269|PubMed:22976764,
FT                                ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071641.
FT   VARIANT     330    330       G -> R (in CDG1T; decreases mildly
FT                                solubility; dbSNP:rs777164338).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071642.
FT   VARIANT     377    377       E -> K (in CDG1T; decreases strongly
FT                                solubility).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071643.
FT   VARIANT     388    388       E -> K (in CDG1T; decreases strongly
FT                                solubility).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071644.
FT   VARIANT     420    420       Y -> H (in allele PGM1*1-, allele
FT                                PGM1*2-, allele PGM1*3- and allele
FT                                PGM1*7-; phosphoglucomutase activity is
FT                                similar to wild-type; dbSNP:rs11208257).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:25288802,
FT                                ECO:0000269|PubMed:7902567,
FT                                ECO:0000269|PubMed:7902568,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_006092.
FT   VARIANT     501    501       V -> I (in dbSNP:rs6676290).
FT                                /FTId=VAR_034380.
FT   VARIANT     516    516       L -> P (in CDG1T; decreases strongly
FT                                solubility; dbSNP:rs587777401).
FT                                {ECO:0000269|PubMed:24499211,
FT                                ECO:0000269|PubMed:25288802}.
FT                                /FTId=VAR_071645.
FT   CONFLICT    134    134       S -> C (in Ref. 5; AAH67763).
FT                                {ECO:0000305}.
FT   STRAND        5      8       {ECO:0000244|PDB:5JN5}.
FT   TURN         18     20       {ECO:0000244|PDB:5JN5}.
FT   STRAND       22     25       {ECO:0000244|PDB:5JN5}.
FT   HELIX        26     31       {ECO:0000244|PDB:5JN5}.
FT   STRAND       32     34       {ECO:0000244|PDB:5HSH}.
FT   HELIX        35     44       {ECO:0000244|PDB:5JN5}.
FT   HELIX        49     51       {ECO:0000244|PDB:5JN5}.
FT   TURN         52     54       {ECO:0000244|PDB:5JN5}.
FT   STRAND       56     61       {ECO:0000244|PDB:5JN5}.
FT   HELIX        67     80       {ECO:0000244|PDB:5JN5}.
FT   STRAND       85     93       {ECO:0000244|PDB:5JN5}.
FT   HELIX        96    106       {ECO:0000244|PDB:5JN5}.
FT   STRAND      109    114       {ECO:0000244|PDB:5JN5}.
FT   STRAND      125    133       {ECO:0000244|PDB:5JN5}.
FT   STRAND      136    138       {ECO:0000244|PDB:5JN5}.
FT   HELIX       141    153       {ECO:0000244|PDB:5JN5}.
FT   STRAND      156    159       {ECO:0000244|PDB:5JN5}.
FT   STRAND      171    177       {ECO:0000244|PDB:5JN5}.
FT   STRAND      184    189       {ECO:0000244|PDB:5JN5}.
FT   HELIX       193    202       {ECO:0000244|PDB:5JN5}.
FT   HELIX       205    212       {ECO:0000244|PDB:5JN5}.
FT   STRAND      220    223       {ECO:0000244|PDB:5JN5}.
FT   STRAND      227    229       {ECO:0000244|PDB:5F9C}.
FT   HELIX       230    236       {ECO:0000244|PDB:5JN5}.
FT   TURN        237    241       {ECO:0000244|PDB:5JN5}.
FT   HELIX       245    247       {ECO:0000244|PDB:5JN5}.
FT   STRAND      248    250       {ECO:0000244|PDB:5JN5}.
FT   HELIX       257    259       {ECO:0000244|PDB:5JN5}.
FT   TURN        266    269       {ECO:0000244|PDB:5JN5}.
FT   HELIX       270    277       {ECO:0000244|PDB:5JN5}.
FT   STRAND      282    287       {ECO:0000244|PDB:5JN5}.
FT   STRAND      291    298       {ECO:0000244|PDB:5JN5}.
FT   HELIX       299    301       {ECO:0000244|PDB:5JN5}.
FT   STRAND      302    304       {ECO:0000244|PDB:5HSH}.
FT   HELIX       306    315       {ECO:0000244|PDB:5JN5}.
FT   HELIX       316    319       {ECO:0000244|PDB:5JN5}.
FT   HELIX       321    326       {ECO:0000244|PDB:5JN5}.
FT   STRAND      331    334       {ECO:0000244|PDB:5JN5}.
FT   HELIX       340    348       {ECO:0000244|PDB:5JN5}.
FT   STRAND      352    355       {ECO:0000244|PDB:5JN5}.
FT   HELIX       359    367       {ECO:0000244|PDB:5JN5}.
FT   STRAND      372    376       {ECO:0000244|PDB:5JN5}.
FT   TURN        377    379       {ECO:0000244|PDB:5JN5}.
FT   STRAND      380    383       {ECO:0000244|PDB:5JN5}.
FT   STRAND      386    388       {ECO:0000244|PDB:5JN5}.
FT   HELIX       391    405       {ECO:0000244|PDB:5JN5}.
FT   HELIX       409    420       {ECO:0000244|PDB:5JN5}.
FT   STRAND      422    433       {ECO:0000244|PDB:5JN5}.
FT   HELIX       435    450       {ECO:0000244|PDB:5JN5}.
FT   STRAND      458    460       {ECO:0000244|PDB:5JN5}.
FT   STRAND      465    473       {ECO:0000244|PDB:5JN5}.
FT   TURN        479    481       {ECO:0000244|PDB:5JN5}.
FT   STRAND      490    494       {ECO:0000244|PDB:5JN5}.
FT   STRAND      499    504       {ECO:0000244|PDB:5JN5}.
FT   STRAND      512    522       {ECO:0000244|PDB:5JN5}.
FT   TURN        525    529       {ECO:0000244|PDB:5JN5}.
FT   HELIX       532    547       {ECO:0000244|PDB:5JN5}.
FT   HELIX       549    553       {ECO:0000244|PDB:5JN5}.
FT   STRAND      559    562       {ECO:0000244|PDB:5JN5}.
SQ   SEQUENCE   562 AA;  61449 MW;  61A26C19107D467A CRC64;
     MVKIVTVKTQ AYQDQKPGTS GLRKRVKVFQ SSANYAENFI QSIISTVEPA QRQEATLVVG
     GDGRFYMKEA IQLIARIAAA NGIGRLVIGQ NGILSTPAVS CIIRKIKAIG GIILTASHNP
     GGPNGDFGIK FNISNGGPAP EAITDKIFQI SKTIEEYAVC PDLKVDLGVL GKQQFDLENK
     FKPFTVEIVD SVEAYATMLR SIFDFSALKE LLSGPNRLKI RIDAMHGVVG PYVKKILCEE
     LGAPANSAVN CVPLEDFGGH HPDPNLTYAA DLVETMKSGE HDFGAAFDGD GDRNMILGKH
     GFFVNPSDSV AVIAANIFSI PYFQQTGVRG FARSMPTSGA LDRVASATKI ALYETPTGWK
     FFGNLMDASK LSLCGEESFG TGSDHIREKD GLWAVLAWLS ILATRKQSVE DILKDHWQKY
     GRNFFTRYDY EEVEAEGANK MMKDLEALMF DRSFVGKQFS ANDKVYTVEK ADNFEYSDPV
     DGSISRNQGL RLIFTDGSRI VFRLSGTGSA GATIRLYIDS YEKDVAKINQ DPQVMLAPLI
     SIALKVSQLQ ERTGRTAPTV IT
//
